Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2022 09:00 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022

Highlights: Revenue of $164.9 million for the quarter ended March 31, 2022 Excluding revenue from divested businesses, revenue increased 11% year-over-year Diluted GAAP...
May 04, 2022 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare Conference

SALT LAKE CITY, May 04, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be discussing the...
May 03, 2022 16:15 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise™ Oncology Solutions

Precise™ Liquid Biopsy will provide insights on circulating tumor DNA in the blood to help guide cancer treatment decisions SALT LAKE CITY, May 03, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.,...
April 28, 2022 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Release First-Quarter 2022 Financial Results on May 5, 2022

SALT LAKE CITY, April 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first-quarter 2022 earnings conference...
April 26, 2022 07:05 ET | Source: Myriad Genetics, Inc.

2 Out of 3 Women With Depression or Anxiety Say They’ve Reached Their “Breaking Point” Yet More than Half Wait a Year Before Seeking Treatment

SALT LAKE CITY, April 26, 2022 (GLOBE NEWSWIRE) -- Two out of three women diagnosed with depression or anxiety say they have reached or are approaching their breaking point regarding their mental...
March 14, 2022 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care

SALT LAKE CITY, March 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of Precise™ Oncology...
March 11, 2022 19:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer

SALT LAKE CITY, March 11, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the U.S. Food and Drug Administration...
March 08, 2022 07:22 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies

Myriad to establish new Walter Gilbert Research and Innovation Center Company also cited among 2022 Top Workplaces USA National List by Energage SALT LAKE CITY, March 08, 2022 (GLOBE NEWSWIRE)...
March 02, 2022 16:30 ET | Source: Myriad Genetics, Inc.

Myriad Genetics CEO Paul Diaz to Speak at 42nd Annual Cowen Health Care Conference

SALT LAKE CITY, March 02, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be participating...
February 24, 2022 09:00 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives

Highlights: Strong business performance despite COVID-19 headwindsRevenue of $160.8 million in the fourth quarter and $690.6 million for the year ended Dec. 31, 2021, up 4% and 24%, respectively...